BiotechTube
Transgene SA

Transgene SA

TNG.PAPre-clinical
150-250 employeestransgene.fr

Transgene SA is a clinical-stage biotech company developing a new generation of immunotherapies to treat cancer. Its core expertise lies in engineering viral vectors, including Vaccinia and Adenovirus platforms, to stimulate the patient's immune system against tumors. The company has built a diversified pipeline of oncolytic viruses and therapeutic vaccines, primarily in Phase 1 and 2 trials, and maintains strategic collaborations with major players like Institut Mérieux and NEC Corporation. Its strategy is to advance its lead candidates while expanding its technology's application through partnerships.

Market Cap
$236.4M
+12.8% period
Pipeline
—
Patents
—
Publications
—

TNG.PA · Stock Price

USD 0.75+0.09 (+12.82%)

Historical price data

AI Company Overview

Transgene SA is a clinical-stage biotech company developing a new generation of immunotherapies to treat cancer. Its core expertise lies in engineering viral vectors, including Vaccinia and Adenovirus platforms, to stimulate the patient's immune system against tumors. The company has built a diversified pipeline of oncolytic viruses and therapeutic vaccines, primarily in Phase 1 and 2 trials, and maintains strategic collaborations with major players like Institut Mérieux and NEC Corporation. Its strategy is to advance its lead candidates while expanding its technology's application through partnerships.

Oncology

Technology Platform

Proprietary viral vector platforms including the Invir.IO™ oncolytic virus platform for armed Vaccinia-based therapies and the myvac® platform for personalized neoantigen cancer vaccines.

Funding History

2
Total raised:$25.5M
PIPE$25.5MJun 15, 2021
IPOUndisclosedJun 15, 1998

Opportunities

Significant growth opportunity lies in demonstrating clinical proof-of-concept for its armed oncolytic viruses (BT-001) and personalized vaccine platform (TG4050), which could lead to lucrative partnerships or acquisition interest.
The expanding immuno-oncology market, especially for combination therapies and personalized approaches, provides a large addressable market for its technology.

Risk Factors

Key risks include clinical trial failures, the high cash burn rate of a clinical-stage biotech requiring frequent dilutive financing, intense competition from larger immuno-oncology players, and the complex regulatory pathway for novel biological therapies like oncolytic viruses.

Competitive Landscape

Transgene competes with other oncolytic virus developers (e.g., Amgen, Replimune) and cancer vaccine companies (e.g., BioNTech, Moderna). Its differentiation is based on its proprietary, armed viral vector platforms (Invir.IO™, myvac®) and integrated manufacturing capabilities, aiming to create more potent and targeted immunotherapies.